Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those postponed,...read more
Proteon Therapeutics, which is developing a treatment to reduce the failure rates of a dialysis-related procedure, raised $61 million by offering 6.1 million shares at $10, below the range of $12 to $14. Proteon Therapeutics plans to list on the NASDAQ under the...read more
5 IPOs are expected to raise $456 million during the week of October 20. After five straight weeks of raising over $1 billion, the IPO market appears to have chilled due to the broader market selloff and weaker returns. Aside from two small health care companies...read more
Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $61 million by offering 4.7 million shares at a price range...read more
US IPO Weekly Recap: With just 3 IPOs, more companies postpone than go public
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those postponed,...read more
Proteon Therapeutics prices IPO at $10, below the range
Proteon Therapeutics, which is developing a treatment to reduce the failure rates of a dialysis-related procedure, raised $61 million by offering 6.1 million shares at $10, below the range of $12 to $14. Proteon Therapeutics plans to list on the NASDAQ under the...read more
Week Ahead: 5 IPOs planned for the week of October 20 include e-cigarettes and asset management
5 IPOs are expected to raise $456 million during the week of October 20. After five straight weeks of raising over $1 billion, the IPO market appears to have chilled due to the broader market selloff and weaker returns. Aside from two small health care companies...read more
Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO
Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $61 million by offering 4.7 million shares at a price range...read more